无进展生存期-话题@MedSci

#无进展生存期#

56篇内容 | 2160人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2237333, encodeId=abfd223e33377, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a> 多年来，雄激素剥夺疗法（ADT）一直是治疗转移性激素敏感性前列腺癌（mHSPC）和转移性去势抵抗性前列腺癌（mCRPC）的金标准疗法。多西他赛化疗或雄激素信号受体抑制剂 (ARSI) 等新型附加组合疗法可大幅延长mHSPC的总生存期 (OS) 和发展为mCRPC 的时间。然而，与mHSPC相比，当达到去势抵抗状态时，转移性疾病将成为一种致死率极高的疾病，预期寿命也会缩短。, objectTitle=无进展生存期, objectType=topic, longId=59168, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=4, createdTime=2024-11-17, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2237258, encodeId=837f223e25834, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a> <a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a> <a href='/topic/show?id=a17393408d0' target=_blank style='color:#2F92EE;'>#转移性去势抵抗性前列腺癌#</a>, objectTitle=World J Urol：转移部位和负担对转移性去势抵抗性前列腺癌患者肿瘤预后的影响, objectType=article, longId=850853, objectId=10588508533c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241111/1731339823394_1935437.jpg, objectUrl=/article/show_article.do?id=10588508533c, replyNumber=0, likeNumber=15, createdTime=2024-11-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=10588508533c, moduleTitle=World J Urol：转移部位和负担对转移性去势抵抗性前列腺癌患者肿瘤预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10588508533c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2219024, encodeId=752122190243c, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a> <a href='/topic/show?id=6b0711e64262' target=_blank style='color:#2F92EE;'>#原发灶不明确的癌症#</a> <a href='/topic/show?id=427d11e64343' target=_blank style='color:#2F92EE;'>#分子引导治疗#</a>, objectTitle=近5%的肿瘤为“幻影癌症”，但三分之一的患者能用上靶向药！, objectType=article, longId=837614, objectId=316883e61476, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719539222993_5579292.jpg, objectUrl=/article/show_article.do?id=316883e61476, replyNumber=0, likeNumber=84, createdTime=2024-08-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=316883e61476, moduleTitle=近5%的肿瘤为“幻影癌症”，但三分之一的患者能用上靶向药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=316883e61476)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1459692, encodeId=6c4b145969288, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%, objectType=article, longId=728906, objectId=8ed1e2890609, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed1e2890609, replyNumber=0, likeNumber=87, createdTime=2022-06-10, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed1e2890609, moduleTitle=NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ed1e2890609)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459691, encodeId=b2ef145969182, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, objectType=article, longId=727501, objectId=ccafe275011b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccafe275011b, replyNumber=0, likeNumber=58, createdTime=2022-05-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccafe275011b, moduleTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccafe275011b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459690, encodeId=77a1145969006, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=74, createdTime=2022-04-12, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459689, encodeId=6f60145968916, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍, objectType=article, longId=293793, objectId=02ce293e9390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce293e9390, replyNumber=0, likeNumber=80, createdTime=2022-01-12, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce293e9390, moduleTitle=NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce293e9390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459688, encodeId=d541145968832, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=J Clin Oncol：二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, objectType=article, longId=291938, objectId=b40f29193897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40f29193897, replyNumber=0, likeNumber=78, createdTime=2021-12-17, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40f29193897, moduleTitle=J Clin Oncol：二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40f29193897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459687, encodeId=cb16145968e65, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, objectType=article, longId=217398, objectId=e57c21e398b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57c21e398b5, replyNumber=0, likeNumber=88, createdTime=2021-09-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57c21e398b5, moduleTitle=J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57c21e398b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459686, encodeId=9743145968641, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期, objectType=article, longId=212407, objectId=dc0d21240ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc0d21240ed5, replyNumber=0, likeNumber=0, createdTime=2021-06-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc0d21240ed5, moduleTitle=ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc0d21240ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459685, encodeId=b69d1459685e2, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, objectType=article, longId=211652, objectId=9a1e21165207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1e21165207, replyNumber=0, likeNumber=92, createdTime=2021-05-23, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1e21165207, moduleTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1e21165207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459684, encodeId=b1c014596842d, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, objectType=article, longId=207681, objectId=b94020e681d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94020e681d7, replyNumber=0, likeNumber=81, createdTime=2021-02-28, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94020e681d7, moduleTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94020e681d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459683, encodeId=709a1459683ff, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, objectType=article, longId=203482, objectId=6ec6203482bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec6203482bb, replyNumber=0, likeNumber=63, createdTime=2020-11-18, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec6203482bb, moduleTitle=The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ec6203482bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459682, encodeId=a94b14596829c, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, objectType=article, longId=199750, objectId=6fb7199e501c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb7199e501c, replyNumber=0, likeNumber=78, createdTime=2020-08-22, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb7199e501c, moduleTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb7199e501c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459681, encodeId=5997145968158, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=0, createdTime=2020-08-13, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459680, encodeId=cfe11459680ca, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=78, createdTime=2020-08-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459679, encodeId=41aa14596e910, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, objectType=article, longId=198728, objectId=a9fa198e28d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9fa198e28d9, replyNumber=0, likeNumber=71, createdTime=2020-08-06, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9fa198e28d9, moduleTitle=PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9fa198e28d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459678, encodeId=b03014596e89a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=184850, objectId=079b184850dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079b184850dc, replyNumber=0, likeNumber=69, createdTime=2019-12-18, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079b184850dc, moduleTitle=2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=079b184850dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459677, encodeId=1f9f14596e76e, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=50, createdTime=2019-12-14, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459676, encodeId=844a14596e6b5, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=67, createdTime=2019-10-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

无进展生存期

2020-05-29

yangchou (审核中...)

前往app查看评论内容

全文收起 #无进展生存期# 多年来，雄激素剥夺疗法（ADT）一直是治疗转移性激素敏感性前列腺癌（mHSPC）和转移性去势抵抗性前列腺癌（mCRPC）的金标准疗法。多西他赛化疗或雄激素信号受体抑制剂 (ARSI) 等新型附加组合疗法可大幅延长mHSPC的总生存期 (OS) 和发展为mCRPC 的时间。然而，与mHSPC相比，当达到去势抵抗状态时，转移性疾病将成为一种致死率极高的疾病，预期寿命也会缩短。

2024-11-17发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#无进展生存期# #总生存期# #转移性去势抵抗性前列腺癌#

World J Urol：转移部位和负担对转移性去势抵抗性前列腺癌患者肿瘤预后的影响

2024-11-16发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#无进展生存期# #原发灶不明确的癌症# #分子引导治疗#

近5%的肿瘤为“幻影癌症”，但三分之一的患者能用上靶向药！

2024-08-07发表于上海

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：ADC药物效果惊艳，延长晚期乳腺癌患者无进展生存期50%

2022-06-10

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响

2022-05-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-04-12

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：第三代免疫检查点上场：LAG-3+PD-1，晚期癌症无进展生存期提高一倍

2022-01-12

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

J Clin Oncol：二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！

2021-12-17

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

J Clin Oncol：3期| 二线化疗联合钇90放射栓塞可显著延长结直肠癌肝转移患者的无进展生存期！

2021-09-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

ASCO-2021速递: 哈佛大学:乳腺癌药物，可延长胶质母细胞瘤的无进展生存期

2021-06-08

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期

2021-05-23

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！

2021-02-28

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

The Lancet：核出口抑制剂XPOVIO显著延长复发或难治性多发性骨髓瘤患者的无进展生存期

2020-11-18

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期

2020-08-22

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2020-08-13

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2020-08-08

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

PD-1单抗Opdivo联合贝伐单抗和化疗：显着改善非小细胞肺癌患者的无进展生存期

2020-08-06

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 ASH：阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

2019-12-18

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2019-12-14

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

科室
- - 订阅+
  - 更多科室
工具
服务